Terms: = Breast cancer AND MTCP1, C6_1B, 4515, ENSG00000214827, GS1-273L24_4 AND Clinical Outcome
730 results:
1. Tumor budding in breast carcinoma: A systematic review and meta-analysis.
Buch A; Khan U; Rathod H; Jain K; Dwivedi A; Rajesh A
J Cancer Res Ther; 2023 Oct; 19(7):1697-1713. PubMed ID: 38376268
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes.
Dimitrakopoulos FI; Goussia A; Koliou GA; Dadouli K; Batistatou A; Kourea HP; Bobos M; Arapantoni-Dadioti P; Tzaida O; Koletsa T; Chrisafi S; Sotiropoulou M; Papoudou-Bai A; Nicolaou I; Charchanti A; Mauri D; Aravantinos G; Binas I; Res E; Psyrri A; Pectasides D; Bafaloukos D; Koumarianou A; Bompolaki I; Rigakos G; Karanikiotis C; Koutras A; Zagouri F; Gogas H; Fountzilas G
Breast; 2024 Feb; 73():103668. PubMed ID: 38176305
[TBL] [Abstract] [Full Text] [Related]
4. clinical characteristics and prognosis of primary small cell carcinoma of the breast: a propensity score-matched, population-based study.
Yin L; Yin AH; Pu CC
BMJ Open; 2023 Dec; 13(12):e073841. PubMed ID: 38097248
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of Circulating Tumor DNA Assays for Molecular Residual Disease Detection in Early-Stage Triple-Negative breast cancer.
Coakley M; Villacampa G; Sritharan P; Swift C; Dunne K; Kilburn L; Goddard K; Pipinikas C; Rojas P; Emmett W; Hall P; Harper-Wynne C; Hickish T; Macpherson I; Okines A; Wardley A; Wheatley D; Waters S; Palmieri C; Winter M; Cutts RJ; Garcia-Murillas I; Bliss J; Turner NC
Clin Cancer Res; 2024 Feb; 30(4):895-903. PubMed ID: 38078899
[TBL] [Abstract] [Full Text] [Related]
6. A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic breast cancer.
Cescon DW; Hilton J; Morales Murilo S; Layman RM; Pluard T; Yeo B; Park IH; Provencher L; Kim SB; Im YH; Wyce A; Krishnatry AS; Hicks K; Zhang Q; Barbash O; Khaled A; Horner T; Dhar A; Oliveira M; Sparano JA
Clin Cancer Res; 2024 Jan; 30(2):334-343. PubMed ID: 37992310
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
8. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
[TBL] [Abstract] [Full Text] [Related]
9. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Cao J; Teng Y; Li H; Zhang L; Ouyang Q; Xie W; Pan Y; Song Z; Ling X; Wu X; Xu J; Li L; Ren L; Wang H; Zhou D; Luo J; Hu X
BMC Med; 2023 Aug; 21(1):300. PubMed ID: 37559142
[TBL] [Abstract] [Full Text] [Related]
10. Adrenal and periadrenal schwannoma: histological, molecular and clinical characterization of an institutional case series.
Stenman A; Falhammar H; Zedenius J; Juhlin CC
Endocrine; 2023 Dec; 82(3):631-637. PubMed ID: 37535242
[TBL] [Abstract] [Full Text] [Related]
11. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
12. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Harbeck N; Fasching PA; Wuerstlein R; Degenhardt T; Lüftner D; Kates RE; Schumacher J; Räth P; Hoffmann O; Lorenz R; Decker T; Reinisch M; Göhler T; Staib P; Gluz O; Schinköthe T; Schmidt M;
Ann Oncol; 2023 Aug; 34(8):660-669. PubMed ID: 37201751
[TBL] [Abstract] [Full Text] [Related]
13. Epidemiology and a Predictive Model of Prognosis Index Based on Machine Learning in Primary breast Lymphoma: Population-Based Study.
Yu Y; Xu Z; Shao T; Huang K; Chen R; Yu X; Zhang J; Han H; Song C
JMIR Public Health Surveill; 2023 Jun; 9():e45455. PubMed ID: 37169516
[TBL] [Abstract] [Full Text] [Related]
14. DNA aneuploidy identifies a subset of Luminal subtype breast carcinoma patients with worse clinical outcome.
Pinto AE; Matos J; Pereira T; Silva GL; André S
Pathol Res Pract; 2023 Jun; 246():154513. PubMed ID: 37167811
[TBL] [Abstract] [Full Text] [Related]
15. High leukocyte mitochondrial DNA copy number contributes to poor prognosis in breast cancer patients.
Zhang W; Lin S; Zeng B; Chen X; Chen L; Chen M; Guo W; Lin Y; Yu L; Hou J; Li Y; Li S; Jin X; Cai W; Zhang K; Nie Q; Chen H; Li J; He P; Cai Q; Qiu Y; Wang C; Fu F
BMC Cancer; 2023 Apr; 23(1):377. PubMed ID: 37098487
[TBL] [Abstract] [Full Text] [Related]
16. Reducing the Use of Frozen Section for Sentinel Node Biopsy in breast Carcinoma: Feasibility and outcome.
Susini T; Nesi I; Renda I; Giani M; Nori J; Vanzi E; Bianchi S
Anticancer Res; 2023 May; 43(5):2161-2170. PubMed ID: 37097648
[TBL] [Abstract] [Full Text] [Related]
17. Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer.
Godina C; Tryggvadottir H; Bosch A; Borgquist S; Belting M; Isaksson K; Jernström H
Breast Cancer Res Treat; 2023 Jun; 199(2):335-347. PubMed ID: 37017811
[TBL] [Abstract] [Full Text] [Related]
18. Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.
Puisset F; Le Louedec F; Dalenc F; Verguet L; De Maio E; Lacaze JL; Montastruc M; Ung M; Vinson C; Perriat S; Pacher S; Chatelut E; Koning MW
Br J Clin Pharmacol; 2023 Jul; 89(7):2283-2294. PubMed ID: 36854898
[TBL] [Abstract] [Full Text] [Related]
19. Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression.
Shi Q; Yu J; Liu D; Ren F; Wu J; Shen K
BMC Cancer; 2023 Feb; 23(1):173. PubMed ID: 36810001
[TBL] [Abstract] [Full Text] [Related]
20. Treatment and outcome in metastatic lobular breast cancer in the prospective German research platform OPAL.
Thill M; Zahn MO; Welt A; Stickeler E; Nusch A; Fietz T; Rauh J; Wetzel N; Kruggel L; Jänicke M; Marschner N; Harbeck N; Wöckel A; Decker T;
Breast Cancer Res Treat; 2023 Apr; 198(3):545-553. PubMed ID: 36807725
[TBL] [Abstract] [Full Text] [Related]
[Next]
